These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

546 related articles for article (PubMed ID: 25404094)

  • 21. Clinical Efficacy of Romidepsin in Tumor Stage and Folliculotropic Mycosis Fungoides.
    Foss F; Duvic M; Lerner A; Waksman J; Whittaker S
    Clin Lymphoma Myeloma Leuk; 2016 Nov; 16(11):637-643. PubMed ID: 27637428
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Romidepsin Plus Liposomal Doxorubicin Is Safe and Effective in Patients with Relapsed or Refractory T-Cell Lymphoma: Results of a Phase I Dose-Escalation Study.
    Vu K; Wu CH; Yang CY; Zhan A; Cavallone E; Berry W; Heeter P; Pincus L; Wieduwilt MJ; William BM; Andreadis C; Kaplan LK; McCormick F; Porcu P; Brammer JE; Ai WZ
    Clin Cancer Res; 2020 Mar; 26(5):1000-1008. PubMed ID: 31772119
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Mogamulizumab versus vorinostat in previously treated cutaneous T-cell lymphoma (MAVORIC): an international, open-label, randomised, controlled phase 3 trial.
    Kim YH; Bagot M; Pinter-Brown L; Rook AH; Porcu P; Horwitz SM; Whittaker S; Tokura Y; Vermeer M; Zinzani PL; Sokol L; Morris S; Kim EJ; Ortiz-Romero PL; Eradat H; Scarisbrick J; Tsianakas A; Elmets C; Dalle S; Fisher DC; Halwani A; Poligone B; Greer J; Fierro MT; Khot A; Moskowitz AJ; Musiek A; Shustov A; Pro B; Geskin LJ; Dwyer K; Moriya J; Leoni M; Humphrey JS; Hudgens S; Grebennik DO; Tobinai K; Duvic M;
    Lancet Oncol; 2018 Sep; 19(9):1192-1204. PubMed ID: 30100375
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Multicenter phase II study of mogamulizumab (KW-0761), a defucosylated anti-cc chemokine receptor 4 antibody, in patients with relapsed peripheral T-cell lymphoma and cutaneous T-cell lymphoma.
    Ogura M; Ishida T; Hatake K; Taniwaki M; Ando K; Tobinai K; Fujimoto K; Yamamoto K; Miyamoto T; Uike N; Tanimoto M; Tsukasaki K; Ishizawa K; Suzumiya J; Inagaki H; Tamura K; Akinaga S; Tomonaga M; Ueda R
    J Clin Oncol; 2014 Apr; 32(11):1157-63. PubMed ID: 24616310
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Resminostat in patients with relapsed or refractory Hodgkin lymphoma: results of the phase II SAPHIRE study.
    Walewski J; Paszkiewicz-Kozik E; Borsaru G; Hellmann A; Janikova A; Warszewska A; Mais A; Ammendola A; Herz T; Krauss B; Henning SW
    Leuk Lymphoma; 2019 Mar; 60(3):675-684. PubMed ID: 30160566
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Histone Deacetylase Inhibitors for Cutaneous T-Cell Lymphoma.
    Duvic M
    Dermatol Clin; 2015 Oct; 33(4):757-64. PubMed ID: 26433847
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Romidepsin for the treatment of relapsed/refractory peripheral T cell lymphoma: prolonged stable disease provides clinical benefits for patients in the pivotal trial.
    Foss F; Horwitz S; Pro B; Prince HM; Sokol L; Balser B; Wolfson J; Coiffier B
    J Hematol Oncol; 2016 Mar; 9():22. PubMed ID: 26965915
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Romidepsin: in the treatment of T-cell lymphoma.
    Yang LP
    Drugs; 2011 Jul; 71(11):1469-80. PubMed ID: 21812508
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Phase II trial of zanolimumab (HuMax-CD4) in relapsed or refractory non-cutaneous peripheral T cell lymphoma.
    d'Amore F; Radford J; Relander T; Jerkeman M; Tilly H; Osterborg A; Morschhauser F; Gramatzki M; Dreyling M; Bang B; Hagberg H
    Br J Haematol; 2010 Sep; 150(5):565-73. PubMed ID: 20629661
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Phase II trial of the histone deacetylase inhibitor belinostat in women with platinum resistant epithelial ovarian cancer and micropapillary (LMP) ovarian tumours.
    Mackay HJ; Hirte H; Colgan T; Covens A; MacAlpine K; Grenci P; Wang L; Mason J; Pham PA; Tsao MS; Pan J; Zwiebel J; Oza AM
    Eur J Cancer; 2010 Jun; 46(9):1573-9. PubMed ID: 20304628
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Paclitaxel/carboplatin with or without belinostat as empiric first-line treatment for patients with carcinoma of unknown primary site: A randomized, phase 2 trial.
    Hainsworth JD; Daugaard G; Lesimple T; Hübner G; Greco FA; Stahl MJ; Büschenfelde CM; Allouache D; Penel N; Knoblauch P; Fizazi KS
    Cancer; 2015 May; 121(10):1654-61. PubMed ID: 25611313
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A phase 2, multicentre, single-arm, open-label study to evaluate the safety and efficacy of single-agent lenalidomide (Revlimid) in subjects with relapsed or refractory peripheral T-cell non-Hodgkin lymphoma: the EXPECT trial.
    Morschhauser F; Fitoussi O; Haioun C; Thieblemont C; Quach H; Delarue R; Glaisner S; Gabarre J; Bosly A; Lister J; Li J; Coiffier B
    Eur J Cancer; 2013 Sep; 49(13):2869-76. PubMed ID: 23731832
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Vorinostat for refractory or relapsing epidermotropic T-cell lymphoma: a retrospective cohort study of 15 patients.
    Kogge A; Volteau C; Saint-Jean M; Peuvrel L; Brocard A; Knol AC; Renaut JJ; Dréno B; Quéreux G
    Acta Derm Venereol; 2015 Jan; 95(1):72-7. PubMed ID: 24806744
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Belinostat: clinical applications in solid tumors and lymphoma.
    Molife LR; de Bono JS
    Expert Opin Investig Drugs; 2011 Dec; 20(12):1723-32. PubMed ID: 22046971
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Phase Ia/II, two-arm, open-label, dose-escalation study of oral panobinostat administered via two dosing schedules in patients with advanced hematologic malignancies.
    DeAngelo DJ; Spencer A; Bhalla KN; Prince HM; Fischer T; Kindler T; Giles FJ; Scott JW; Parker K; Liu A; Woo M; Atadja P; Mishra KK; Ottmann OG
    Leukemia; 2013 Aug; 27(8):1628-36. PubMed ID: 23385375
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Phase III placebo-controlled trial of denileukin diftitox for patients with cutaneous T-cell lymphoma.
    Prince HM; Duvic M; Martin A; Sterry W; Assaf C; Sun Y; Straus D; Acosta M; Negro-Vilar A
    J Clin Oncol; 2010 Apr; 28(11):1870-7. PubMed ID: 20212249
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Pilot study of denileukin diftitox alternate dosing regimen in patients with cutaneous peripheral T-cell lymphomas.
    Talpur R; Duvic M
    Clin Lymphoma Myeloma Leuk; 2012 Jun; 12(3):180-5. PubMed ID: 22521504
    [TBL] [Abstract][Full Text] [Related]  

  • 38. UGT genotyping in belinostat dosing.
    Goey AK; Figg WD
    Pharmacol Res; 2016 Mar; 105():22-7. PubMed ID: 26773202
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A phase I clinical trial of the effect of belinostat on the pharmacokinetics and pharmacodynamics of warfarin.
    Agarwal N; McPherson JP; Bailey H; Gupta S; Werner TL; Reddy G; Bhat G; Bailey EB; Sharma S
    Cancer Chemother Pharmacol; 2016 Feb; 77(2):299-308. PubMed ID: 26719074
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Histone deacetylase inhibitors: novel agents in cancer treatment.
    Glass E; Viale PH
    Clin J Oncol Nurs; 2013 Feb; 17(1):34-40. PubMed ID: 23372094
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 28.